Oxford Spin-Out Just Raised $300M to Disrupt Biotech

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford, just closed an oversubscribed $300 million Series C round. That's a massive vote of confidence for a company developing small-molecule drugs against some of the toughest targets out there. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson, SV Health Investors, Jefferson Life Sciences, and existing backers like Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. ### Why This Matters OMass isn't your typical biotech. Founded in 2016, it grew out of Professor Dame Carol Robinson's lab at the University of Oxford. The goal? Translate native mass spectrometry research into novel small-molecule therapeutics for historically challenging targets. Their proprietary OdyssION platform combines next-generation native mass spectrometry, novel biochemistry, and custom chemistry to interrogate drug targets within their native ecosystems. In plain English: they can study proteins in their natural environment, giving them cell-system fidelity with cell-free precision. That's a big deal because many diseases are driven by proteins that are hard to drug. OMass's approach could unlock new treatments for conditions that have stumped researchers for years. ### The Pipeline and the Plan The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist. It's being developed for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. The fresh capital will push OMS1620 through Phase 2 clinical trials. And there's more in the pipeline: an SLC15A4 inhibitor poised to follow. > "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow. We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic." – Ros Deegan, CEO of OMass Therapeutics Investors are clearly bullish. "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs," said Evan Greif, Principal at Bain Capital Life Sciences. "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH and look forward to partnering with Ros and the team." Max Klement, Partner at Novo Holdings, added: "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic. Each of these candidates has the potential to address substantial unmet patient needs." ### A Broader European Biotech Boom OMass' round is part of a wave of significant European therapeutics funding in 2026. Here's a quick rundown of other notable rounds: - **Bionyra Pharma** (France): $155 million for inflammatory diseases - **Breye Therapeutics** (Denmark): $73 million for oral small-molecule pipeline - **STORM Therapeutics** (UK): $51 million - **Microbiotica** (UK): $45 million - **Mironid** (UK): $43 million - **Alchemab Therapeutics** (UK): $32 million - **Laigo Bio** (Netherlands): $6 million Together, these deals represent over $400 million in new financing, and with OMass included, that figure jumps to over $700 million. Clearly, European biotech is having a moment. ### What's Next for OMass? With this raise, OMass is well-positioned to advance its pipeline and bring novel therapies to patients. The company's patient-first approach and innovative platform have attracted top-tier investors, and the next few years will be crucial as they move into clinical trials. If successful, OMass could become a major player in endocrinology and immunology, and a poster child for European biotech innovation. For those following the EU Inc news and European startup incorporation scene, this is a story to watch. It shows how spin-outs from academic institutions can attract serious capital and tackle unmet medical needs. And it's a reminder that breakthrough science, combined with smart business strategy, can truly change lives.